Enovis (NYSE:ENOV – Get Free Report) and KORU Medical Systems (NASDAQ:KRMD – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.
Risk and Volatility
Enovis has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, KORU Medical Systems has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.
Profitability
This table compares Enovis and KORU Medical Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enovis | -52.69% | 8.74% | 4.19% |
| KORU Medical Systems | -6.41% | -15.90% | -9.77% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enovis | 1 | 0 | 6 | 2 | 3.00 |
| KORU Medical Systems | 1 | 1 | 4 | 0 | 2.50 |
Enovis presently has a consensus target price of $47.43, suggesting a potential upside of 108.71%. KORU Medical Systems has a consensus target price of $6.50, suggesting a potential upside of 50.46%. Given Enovis’ stronger consensus rating and higher possible upside, equities analysts clearly believe Enovis is more favorable than KORU Medical Systems.
Insider and Institutional Ownership
98.5% of Enovis shares are owned by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are owned by institutional investors. 2.7% of Enovis shares are owned by company insiders. Comparatively, 20.6% of KORU Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Enovis and KORU Medical Systems”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enovis | $2.25 billion | 0.58 | -$1.18 billion | ($20.71) | -1.10 |
| KORU Medical Systems | $41.13 million | 4.87 | -$2.64 million | ($0.06) | -72.00 |
KORU Medical Systems has lower revenue, but higher earnings than Enovis. KORU Medical Systems is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.
Summary
Enovis beats KORU Medical Systems on 10 of the 15 factors compared between the two stocks.
About Enovis
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
About KORU Medical Systems
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
